The Multi-Protein Reality of Alzheimer's Disease: What the Science Has Known for Decades and What the Field Has Yet to Accept

Session details:

Alzheimer's disease has never been a single-protein problem. As far back as the 1990s, researchers identified alpha-synuclein alongside amyloid and tau in Alzheimer's brains — evidence that the disease's complexity was recognized long before it was widely acted upon. Yet drug development, regulatory frameworks, and clinical trial design have largely remained anchored to single targets, prioritizing one over another instead of designing a more comprehensive treatment approach, and the results have been humbling across the field.
This presentation will trace the scientific case for a multi-protein model of Alzheimer's disease, examine the gap between historical data and clinical trials, outline what a more complete, evidence-driven approach to drug development looks like, and how Annovis has built its therapeutic strategy around exactly that premise.